Lead Product(s): Oxypurinol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Xortx Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2020
Lonza Pharma will be resposible for manufacturing of active pharmaceutical ingredient for XRx-101 and XRx-008 in response to support the drug development and clinical trial process for COVID-19.